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PhosphorylationN-myc downstream-regulated gene 1 (NRDG1) is a stress-induced protein whose putative function is
suppression of tumor metastasis. A recent proteonomic study showed NDRG1 interacts with the molecular
chaperone heat shock protein 90 (Hsp90). From their reported association, we investigated if NDRG1 is
dependent on Hsp90 for its stability and is therefore a yet unidentiﬁed Hsp90 client protein. Here, we
demonstrate that endogenous NDRG1 and Hsp90 physically associate in hepatocellular cancer cell lines.
However, geldanamycin (GA)-mediated inhibition of Hsp90 did not disrupt their interaction or result in
NDRG1 protein destabilization. On the contrary, inhibition of Hsp90 led to a transcriptional increase of
NDRG1 protein which was associated with cell growth arrest. We also observed that GA inhibited the
phosphorylation of NDRG1 by targeting its regulating kinases, serum- and glucocorticoid-induced kinase 1
(SGK1) and glycogen synthase kinase 3 β (GSK3β). We demonstrate that in the presence of GA, GSK3β
protein and activity were decreased thus indicating that Hsp90 is necessary for GSK3β stability. Taken
together, our data demonstrate that NDRG1 is not a classic client protein but interacts with Hsp90 and is still
dually regulated by Hsp90 at a transcriptional and post-translational level. Finally, we suggest for the ﬁrst
time GSK3β as a new client protein of Hsp90.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
N-myc downstream-regulated gene 1 (NDRG1) is overexpressed
in many human cancers. The signiﬁcance of its overexpression is not
fully understood, however it is suspected that NDRG1 may have a
beneﬁcial function, more speciﬁcally, as a suppressor of metastases
[1,2]. In some cancers, loss of NDRG1 expression is correlated with
tumor progression and increased tumor aggressiveness [5,6] and
restoration of NDRG1 expression inhibits tumor cell growth in vitro
[3].
An interesting feature of NDRG1 is that it contains three copies of the
10amino acid tandem repeat sequence (GTRSRSHTSE) in its c-terminus.
These sequences are targeted bymultiple kinases including serum- and
glucocorticoid-induced kinase 1 (SGK1) and glycogen synthase kinase
3 β (GSK3β) [7]. Phosphorylation of NDRG1 is initiated by SGK1 at
the threonine (Thr) residues Thr346, Thr356 and Thr366 in the repeat
sequence, as well as at Thr328 and serine (Ser) Ser330. Once NDRG1 has
been “primed”bySGK1phosphorylation, it becomes a suitable substrateicine, Department of Clinical
ern, Switzerland. Tel.: +41 31
.
l rights reserved.forGSK3β, which targets Ser342, Ser352 and Ser362 also locatedwithin the
repeat.
Ongoing studies that identify the transcriptional regulators or the
post-translational modiﬁers of NDRG1 are helping to deﬁne the func-
tion of this intriguing protein [4]. Several groups have deﬁned proteins
that interact with NDRG1, thus providing valuable information
regarding NDRG1's intracellular networks [8–10]. In particular, its
proposed metastasis suppressor function was supported in a recent
report demonstrating thatNDRG1 interactswith, and is essential for, the
recycling of the cell adhesion protein, E-cadherin [11]. Another
proteomic study found by immunoprecipitation (IP) and liquid chro-
matographymass spectrometry (LC/MS/MS) that NDRG1 interactswith
heat shock protein 90 (Hsp90) in human prostate cancer cells [12].
Hsp90 is a molecular chaperone that is vital for the stabilization
and function of many proteins dysregulated in human cancer such as
steroid receptors, transcription factors and kinases [17–22]. Hsp90
is a ubiquitously expressed protein and is necessary for the matu-
ration and stabilization of its client proteins [13–16]. Hsp90 and its
client proteins interact in a multiprotein complex in association with
cochaperone proteins that are dependent on ATP binding in its
intrinsic ATPase domain. Upon ATP binding and hydrolysis the com-
plex switches to a mature, closed state and additional cochaperones
are recruited to assist conformational maturation of client proteins.
Inhibiting the intrinsic ATPase activity of Hsp90, locks the complex in
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of client proteins via the ubiquitin–proteasome pathway [14,26,27].
Whereas the binding afﬁnity of ATP and ADP to the highly conserved
pocket [23,24] within the NH2-terminal of Hsp90 is very low [25],
Hsp90 inhibitors such as 17-allylamino-17demethoxygeldanomycin
(17-AAG) or 17-dimethylaminoethylamino-17-demethoxy-geldana-
mycin (17-DMAG), derived from the natural Hsp90 inhibitors radiciol
and geldanamycin (GA), have evolved as high-afﬁnity ligands [24].
Inhibition of Hsp90 is currently being investigated as a promising anti-
tumor therapy, by targetingmultiple transforming signaling pathways
involved in tumor development [28]. Initially it was questioned
whether Hsp90 inhibitors would be speciﬁc enough to use as anti-
cancer agents due to the role of Hsp90 in normal cellular homeostasis.
However, Hsp90 is predominantly uncomplexed in healthy cells, while
in tumors, Hsp90 is involved in large protein complexes and has an up
to a 100-fold higher binding afﬁnity for 17-AAG than Hsp90 from
healthy cells [29].
Based on the report that identiﬁedNDRG1 andHsp90 as interacting
proteins [13], the goal of this study was to determine the dependency
of Hsp90 on the expression of NDRG1. We hypothesized that GA-
mediated inhibition of Hsp90would lead to the degradation of NDRG1
protein, thus following the well-characterized fate of other Hsp90
clients. By co-IP, we conﬁrmed that NDRG1 and Hsp90 are interacting
proteins. But, contrary to our hypotheses, our results revealed that GA-
dependent inhibition of Hsp90 did not destabilize NDRG1, but rather
led to the transcriptional up-regulation of its mRNA and protein. With
an increase of NDRG1 protein there was a simultaneous loss of its
phosphorylated form, thus indicating that inhibition of Hsp90 results
in both transcriptional and post-translational modiﬁcations of NDRG1
protein. The loss of phosphorylated NDRG1 is explained by Hsp90-
targeted inhibition of its regulating kinases, SGK-1 and GSK3β.
We demonstrate for the ﬁrst time that Hsp90 maintains the stability
and function of the NDRG1 modifying kinase, GSK3β thus suggesting
GSK3β is a newly deﬁned client of Hsp90.
2. Materials and methods
2.1. Cell culture and reagents
Cell lines were obtained from ATCC® (American Type Culture
Collection, Teddington, Great Britain). The human hepatocellular carci-
noma (HCC) cell lines Hep3B and Huh-7 and the human monocytic
cell line U937 were cultured in Dulbecco's modiﬁed Eagles medium
(DMEM) and supplemented with 10% fetal bovine serum, 100 U ml−1
penicillin and 100μg ml−1 streptomycin (all from Life Technology,
Paisley, Scotland). Primary human hepatocytes were cultured in
Arginine-free William's Medium E (Applichem, Darmstadt, Germany)
supplemented with 0.4 mM Ornithine, 2μg ml−1 Hydrocortisone and
7.5U/500 ml−1 Insulin (Sigma). All cell lines were propagated at 37 °C
in anormoxic atmosphere (21%O2)using a standardCO2 incubator, or in
hypoxic conditions (1.5% O2) using a hypoxia workstation (Ruskinn
Technology Limited, West Yorkshire, UK). GA and 17-DMAG (Kosan
Bioscience, California, USA) were dissolved in DMSO to a stock con-
centration of 20 mM and then further diluted in aqueous medium.
Cyclohexamide (CHX) was purchased from Sigma. Hepatocytes were
isolated from operative specimens obtained from consenting patients
requiring hepatic resections at Department of Visceral Surgery and
Medicine, University Hospital of Bern.
2.2. Protein isolation and Western blot analysis
Total protein lysates (TCL) were extracted by standard procedures
using a RIPA buffer (50 mM Tris (pH 7.4), 1 mM EDTA, 150 mM NaCl
and 1% NP-40 supplemented with 1 mM NaF, 1 mM Na3VO4, 1 mM
PMSF and 1× protease inhibitor cocktail (P-8340, Sigma). Proteins
were quantiﬁed using the BioRad Protein Assay (BioRad Laboratories,Reinach, Switzerland). Fifty micrograms of protein were separated by
gel electrophoresis (10% SDS-PAGE) and transferred to a nitrocellu-
losemembrane using a semidry transfer system (BioRad). Membranes
were blocked with 4% nonfat milk in PBS (or TBS (25 mM Tris, pH 7.4,
125mN NaCl) for incubation with GSK3β) for 1h at room tempera-
ture followed by incubation with primary antibodies that recognize
NDRG1 (AB-160) and NDRG1 phosphorylated at Thr346, Thr356 and
Thr366 (anti-p3xThr, PB-025) (both from Kinasource Limited, Scot-
land, UK), Hsp90 (SC#7947, Santa Cruz), GSK3β (#9315) and
phospho-β-catenin (#9561, Cell Signaling Technology, Danvers, MA,
USA) or α-tubulin (T6074, Sigma). The membranes were washed
three times with PBS (or TBS for GSK3β), followed by incubation with
the appropriate horseradish peroxidase conjugated secondary anti-
body. After washing three times, signals were detected by enhanced
chemiluminescence (LiteAblot, Euroclone, SpA, Lugano, Switzerland
or SuperSignal®, Pierce, Rockford IL, USA).
2.3. Quantitative real time RT-PCR
Total RNA was isolated with TRIzol® (Life Technologies, Paisley,
Scotland) according to the manufacturer's instructions. One micro-
gram of total RNA was reverse transcribed into cDNA (Qiagen, Hilden,
Germany). FAM™ dye-labeled TaqMan® probes and polymerase
chain reaction (PCR) primers were purchased at Applied Biosystems
(Rotkreuz, Switzerland). As an internal positive control, ribosomal
18Swas used with the VIC® dye-labeled TaqMan® probe. RT-PCRwas
performed using an ABI PRISM™ 7000 Sequence Detection System
(Applied Biosystems). Ampliﬁcation was carried out for 40cycles at
95 °C for 15s (denaturation step) and 60 °C for 1min (combined
annealing-extension step). The Ct values for each target gene were
standardized against ribosomal RNA (18S). ΔΔCt values were calcu-
lated by subtracting the ΔCt values of cells under standard culture
conditions from theΔCt value of cells cultured in 17-DMAG or GA. Fold
increases were calculated using the formula 2−ΔΔCt. All reactions were
preformed in triplicate and each experiment was conducted on three
independent occasions.
2.4. Co-immunoprecipitation
Protein isolation was carried out as previously described (see
Western blot analysis). A total of 500μg of protein was incubated with
1μg of the appropriate primary antibody over night at 4 °C. The super-
natants were incubated for a further 1h at 4 °C together with 50μg of
Protein G magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany). After calibration, each column was loaded with the sample
and washed four times with a high salt buffer (10 mM Tris, pH 7.5,
300 mMNaCl) followedby onewashwith a low salt buffer (10 mMTris,
pH 7.5, 50 mM NaCl). After washing, the beads were boiled with SDS
sample buffer and analyzed by SDS-PAGE 10% according to standard
protocols.
2.5. Fluorescence-activated cell sorting (FACS)
Cells and the supernatants were harvested, washed in cold PBS and
re-suspended in propidium iodide (PI) solution containing RNAse A
(50 µg PI+40 µg RNAse A/1 ml PBS). The cells were analyzed by FACS
(Becton Dickinson AG, Basel, Switzerland) for PI incorporation after a
minimal incubation time of 30min. The sub-G1 phase cell population
was determined using the FlowJo software (FlowJo, Ashland, OR).
3. Results
3.1. Endogenous NDRG1 and Hsp90 physically interact in Hep3B cells
Hsp90 was recently identiﬁed as an NDRG1-interacting protein by
IP and LC/MS/MS [12]. By Co-IP, we ﬁrst veriﬁed an interaction of
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line, Hep3B. Hep3B cells express a low level of NDRG1 under normal
culture conditions; therefore hypoxic stress was used to increase its
endogenous levels [30]. An increase of NDRG1 protein was detected in
total cell lysates of hypoxic Hep3B cells as well as proteins immuno-
precipitated with an antibody speciﬁc to NDRG1 (Fig. 1). In proteins
immunoprecipitated with NDRG1, a positive signal was detected for
Hsp90 thus indicating that Hsp90 and NDRG1 are associated in Hep3B
cells (Fig. 1). This result supports that NDRG1 is a stress-induced
protein and interaction between NDRG1 and Hsp90 as predicted by
the above-mentioned proteomic study. Stress-induced proteins are
often misfolded during their maturation. This prompted us to hypoth-
esize that NDRG1 requires the chaperone function of Hsp90 for its
proper folding, and therefore may be deﬁned as a client protein of
Hsp90.Fig. 2. Inhibition of Hsp90 up-regulates NDRG1 protein and blocks its phosphorylation.
A) Huh-7 and B) Hep3B cells were incubated with increasing concentrations of GA or
17-DMAG for 24h. TCL were separated by SDS-page. NDRG1 (43 kD), phospho-NDRG1
(anti-p3xThr, N43 kD) α-tubulin (50 kD), used for a loading control were detected by
Western blot. The arrows indicate the faster and slower migrating bands according to
their separation by molecular weight. The experiment was performed on ﬁve3.2. GA-induced inhibition of Hsp90 up-regulates NDRG1 protein and
inhibits its phosphorylation
To determine if NDRG1 is a client of Hsp90, we ﬁrst examined the
consequence of inhibiting Hsp90 activity on the constitutive levels of
NDRG1 in two HCC cell lines, Huh-7 and Hep3B. It is well documented
that inhibiting the intrinsic ATPase activity of Hsp90 impairs the
stability of its client proteins and leads to their degradation [27,31].
However inhibiting Hsp90 with the ansamycin GA or its derivative,
17-DMAG, led to an unexpected increase of total NDRG1 protein. In
Huh-7 cells, both inhibitors increased NDRG1 protein starting at
0.1 µM (Fig. 2A). In Hep3B cells, NDRG1 protein was increased with
0.1 µM and 0.5 µM of GA and 17-DMAG, respectively (Fig. 2B). Two
distinct bands of NDRG1 were detected in untreated cells (Fig. 2A
and B, lanes 1 and 5). The decrease in electrophoretic mobility of the
slower migrating band is a result of its heavily phosphorylated state
by SGK1 and GSK3β [7]. Synchronized with the increase of total
NDRG1 protein, inhibition of Hsp90 resulted in a loss of its slower
migrating, phosphorylated band. An antibody that recognizes NDRG1
phosphorylated at Thr346, Thr356 and Thr366 by SGK1 conﬁrmed that
the slower migrating band was indeed the phosphorylated form of
NDRG1 (Fig. 2A and B).
We questioned whether the GA-mediated increase of NDRG1
expression was due to de novo expression or if this was simply due to
a shift of the protein as a result of a loss of its phosphorylation. Hep3B
cells were cultured for 24 with 17-DMAG with and without the
protein synthesis inhibitor, cyclohexamide (CHX). NDRG1 proteinFig. 1. Endogenous NDRG1 and Hsp90 co-immunoprecipitate. Hep3B cells were
exposed to normoxia (N: 21% O2) or hypoxia (H: 1.5% O2) for 24h. Total cell lysates
(TCL) and proteins immunoprecipitated (IP) for NDRG1 were separated on a SDS-page
gel. NDRG1 (43 kD) and Hsp90 (90 kD) proteins were detected by Western blot. The
experiment was performed on three independent occasions.
independent occasions. C) Hep3B cells were incubated with increasing concentrations
of 17-DMAG with and without CHX [10 µM]. NDRG1 and α-tubulin were detected by
Western blot. The experiment was performed on two independent occasions.was not upregulated by 17-DMAG in the presence of CHX, thus
proving that de novo protein synthesis of NDRG1 is necessary for its
increased expression (Fig. 2C). Moreover, by quantitative real time
PCR we demonstrate that inhibition of Hsp90 increases NDRG1mRNA
levels. GA and 17-DMAG increased NDRG1mRNA levels 7.7±4.0-fold
and 5.6±3.1-fold in Huh-7 and 10.0±3.3-fold and 20.5±3.4-fold in
Hep3B, respectively Fig. 3A and B). Interestingly, in the presence of
CHX, the up-regulation of NDRG1 mRNA is not impaired, suggesting
that de novo protein synthesis of transcriptional regulators is not
required for the transcriptional increase of NDRG1 by GA (Fig. 3C).
And ﬁnally, we tested human hepatocytes isolated from resected liver
tissue. In earlier experiments, we noted that under normal culture
conditions hepatocytes do not express the phosphorylated form of
NDRG1. Consistent with the HCC cell lines, there was a dose depen-
dent increase in the total NDRG1 protein by GA (Fig. 4A) that was
accompanied by a 13.3±0.56-fold increase in its mRNA (Fig. 4B).
Taken together, these data showed that inhibition of Hsp90 activity
did not lead to the hypothesized loss of NDRG1 protein expression but,
Fig. 3. Inhibition of Hsp90 up-regulates NDRG1 mRNA. A) Huh-7 and B) Hep3B cells
were incubated with 1 µM of GA or 17-DMAG for 24h. C) Hep3B cells were incubated
with 1 µM of GA for 2h with and without CHX [10 µM]. Total RNA was isolated and
relative levels of NDRG1 mRNA were determined by quantitative real time PCR. Bars
represent the average fold increase of three independent experiments±the standard
deviation of the mean.
Fig. 4. Inhibition of Hsp90 up-regulates NDRG1 mRNA and protein in human
hepatocytes. A) Hepatocytes were incubated with increasing concentrations of GA for
24h. TCL were separated by SDS-page. NDRG1 (43 kD), phospho-NDRG1 (anti-p3xThr,
N43 kD) and α-tubulin (50 kD) were detected by Western blot. The experiment was
performed on three independent occasions. B) Hepatocytes were incubated with 1 µM
of GA for 24h. Total RNA was isolated and relative levels of NDRG1 mRNA were
determined by quantitative real time PCR. Bars represent the average fold increase of
three independent experiments±the standard deviation of the mean.
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a transcriptional increase of its total mRNA and protein levels with a
concomitant loss of its phosphorylated protein.
3.3. GA-induced up-regulation of NDRG1 is concomitant with cell
growth arrest
We next set out to understand the mechanism by which Hsp90
inhibitors increase NDRG1 mRNA and protein levels. It has been
previously documented that NDRG1 is up-regulated in response to
agents that induce cell growth arrest or cellular differentiation [32].
Therefore we ﬁrst questioned whether the increase of NDRG1 protein
is coupled with GA-induced cell growth arrest. The cell cycle of Hep3Bcells treated with 1 µMGA or 1 µM 17-DMAG for 24hwas analyzed by
ﬂow cytometry. GA and 17-DMAG lead to an increase of cells in G2
(23% control vs 37%GA-treated (p=0.018) and34% 17-DMAG-treated
(p=0.001)) with an associated loss of cells in S phase (25% control vs
13% GA-treated (p=0.013) and 18% 17-DMAG-treated (p=0.021)
(Fig. 5A). The signiﬁcant shift from S to G2 phase conﬁrmed that
inhibition of Hsp90 results in cell growth arrest.
To better distinguish if the increase of NDRG1was a consequence of
GA-induced cell growth arrest or cellular differentiation, we used the
humanmonocytic cell line, U937 treated all-trans retinoic acid (ATRA)
as a control for cellular differentiation. In U937 cells, bothATRA andGA
increased NDRG1 protein levels after 24h (Fig. 5B). In U937 cells
treated with ATRA or GA there was an increase of cells arrested in G1
(36% control vs 50% ATRA-treated and 51% GA-treated (p=0.05) and
an increase of cell arrested in G2 in GA-treated cells (14% control vs
45% GA-treated (p=0.02)) (Fig. 4C). Taken together, ATRA and GA
induce cell growth arrest in U937 cells. And ﬁnally, we used CD11b as a
marker for differentiation and demonstrate an increase of CD11b
in U937 cells treated with ATRA, while no increase of CD11b was
observed in cells treated with GA (Fig. 5D). In summary, inhibition of
Hsp90 induces NDRG1 in associationwith cell growth arrest but in the
absence of cellular differentiation. Interestingly, although GA and
ATRA increasedNDRG1 expression, only cells treatedwith GA resulted
in a loss of phosphorylatedNDRG1 (Fig. 5B).We next set out to explain
howGA-mediated inhibition of Hsp90 blocksNDRG1phosphorylation.
3.4. Interaction between Hsp90 and NDRG1 is independent of Hsp90's
ATPase domain
Chaperone proteins like Hsp90 help maintain the tertiary struc-
tures of their client proteins enabling post-translationalmodiﬁcations.
Fig. 5. Inhibition of Hsp90 leads to cell cycle arrest in Hep3B and U937 cells. A) Hep3B cells were exposed to GA [1 µM] or 17-DMAG [1 µM] for 24h. Cell cycle was analyzed by FACS
and percentages calculated usingWatson Pragmatic analysis. B) U937 cells were incubated with ATRA [1 µM] or GA [1 µM] for 24h. TCL were separated by SDS-page. NDRG1 (43 kD),
phospho-NDRG1 (anti-p3xThr, N43 kD) and α-tubulin (50 kD) were detected by Western blot. The arrows indicate the faster and slower migrating band according to their
separation by molecular weight. C) U937 cells were incubated with ATRA [1 µM] or GA [1 µM] for 24h. Cell cycle was analyzed by FACS and percentages calculated using Watson
Pragmatic analysis. D) U937 cells were incubated with ATRA [1 µM] or GA [1 µM] for 24h. Cells were stained with CD11b and analyzed by FACS. Values are mean ﬂuorescence
intensity measured on FL2 channel. All experiments were performed on at least three independent occasions.
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would disrupt its interaction with NDRG1 thus offering an explanation
for the loss ofNDRG1phosphorylation.Hep3B cellswere incubatedwith
GA or 17-DMAG for 24h and TCL and proteins immunoprecipitated for
NDRG1 were analyzed by Western blot. There was the predicted
increase of NDRG1 protein in the presence of Hsp90 inhibitors. Hsp90
was also detected by co-immunoprecipitation as an NDRG1 interacting
protein in the presence of GA and 17-DMAG (Fig. 6). Taken together,
these data demonstrate that the interaction betweenNDRG1 andHsp90
is not dependent on the ATPase activity of Hsp90. Moreover the loss of
NDRG1 phosphorylation cannot be explained by a disruption of NDRG1
and Hsp90 interaction.Fig. 6. Inhibition of Hsp90 does not impair NDRG1 and Hsp90 interaction. Hep3B cells
were exposed to GA [1 µM] or 17-DMAG [1 µM] for 24h. TCL and proteins IP for NDRG1
were separated on an SDS-page gel. NDRG1 (43 kD) and Hsp90 (90 kD) proteins were
detected by Western blot. The experiment was performed on three independent
occasions.3.5. Hsp90 maintains the stability and function of GSK3β
Wenext focused on the kinases that targetNDRG1. NDRG1 is heavily
phosphorylated in a multistep process involving SGK1 that primes
NDRG1 for subsequent phosphorylation by GSK3β [7]. Due to the
speciﬁcity of the antibody used in this study, we can only hypothesize
that inhibition of Hsp90 blocks SGK1-dependent phosphorylation of
NDRG1. Supporting this hypothesis, SGK1 activity was recently shown
to be directly dependent on Hsp90 [33]. Nonetheless, we questioned if
GSK3β activity is also dependent on Hsp90. As mentioned above, the
stability of Hsp90 client proteins is compromised when its ATPase
activity is impaired [27,34]. In the presence of GA (Fig. 7A) or 17-DMAG
(Fig. 7B), therewas a timedependent decrease of totalGSK3βprotein. In
addition, there was a dose dependent decrease in total GSK3β protein
levels followingexposure toGA for 24h (Fig. 7C).With the loss of GSK3β
protein there was a concomitant loss of phosphorylated β-catenin, a
well documentedGSK3β substrate (Fig. 7C).Moreover, wedemonstrate
by co-IP that Hsp90 and GSK3β are interacting proteins and that their
interaction is disrupted in the cells pre-treatedwith 17-DMAG(Fig. 7D).
Taken together, our results suggest for the ﬁrst time that Hsp90 is
necessary for the stabilization and function of GSK3β, which suggests
GSK3β as a newly identiﬁed client of Hsp90.
4. Discussion
Cancer cells frequently survive in the face of extreme environ-
mental stresses, such as hypoxia or acidosis, as well as to exogenously
applied stresses such as chemo- or radiation therapy. The molecular
chaperone Hsp90, also referred to as the “cancer chaperone”, is
Fig. 7. Stability and function of GSK3β is dependent on Hsp90. Hep3B cells were
incubated with A) GA [1 µM] or B) 17-DMAG [1 µM] for 24 or 36h. C) Hep3B cells were
incubated with increasing concentrations of GA for 24h. TCL were separated by SDS-
page. GSK3β (46 kD) and phospho-β-catenin (94 kD) and α-tubulin (50 kD) were
detected by Western blot. D) GSK3β and Hsp90 co-immunoprecipitation. Hep3B cells
were exposed to 17-DMAG for 24h and IP for GSK3β. Proteins were separated on a SDS-
page gel and immunobloted for Hsp90. Each experiment was performed on three
independent occasions.
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which promote cancer cell growth and/or survival under stressful
conditions [13]. The competitive inhibition of the Hsp90 ATP binding
site results in a loss of interaction between Hsp90 and its clients,
leading to their ubiquitination and consequent proteasomal degra-
dation [27,35]. The importance of HSP90 in human cancers is veriﬁed
by the fact that it is overexpression in many tumors and is currently a
molecular target for therapy [15].
Similar to Hsp90, NDRG1 is also induced by cellular stresses [32,36,
37] and in a proteomic study from Tu et al., preliminary data identiﬁed
NDRG1andHsp90as interactingproteins [12]. AsHsp90 is important for
maturation and activation of stress-related proteins, we investigated
whether NDRG1 is a yet unidentiﬁed client protein of Hsp90. Our data
has demonstrated that unlike the fate of classic Hsp90 client proteins,
GA-mediated inhibition of Hsp90 did not lead to the disruption of
NDRG1:Hsp90 interaction or the subsequent degradation of NDRG1
protein. Instead, GA-induced Hsp90 inhibition resulted in a transcrip-
tional increase of NRDG1 expression in the HCC cell lines, Hep3B
and Huh-7 as well as primary hepatocyte cultures. These data suggest
that even though NDRG1 and Hsp90 are associated, NDRG1 stability
is not dependent on Hsp90. Further studies will reveal if NDRG1 is a
cochaperone protein within the Hsp90 chaperone machine. As a sus-
pected metastasis suppressor protein, it is favorable that NDRG1 is not
degraded by GA-based anti-tumor therapies. Two recently identiﬁed
molecular targets of NDRG1 include thiamine triphosphatase (Thtpa)
and cathepsin C. NDRG1 can reduce cellular levels of Thtpa and
cathepsin C thereby providing an anti-proliferative and anti-metastatic
function, respectively [38].
The exact mechanism of how inhibition of Hsp90 transcriptionally
up-regulates NDRG1 is not yet clear. Hsp90 inhibitors exert an anti-
proliferative effect on tumor cell growth in particular, breast, lym-
phoma and colorectal cancer cells undergo G1 arrest when treated
with GA or its derivative 17-AAG [39–41]. Based on previous studies
that correlated an increase of NDRG1 with cell growth arrest, wehypothesized that the anti-proliferative effect of Hsp90 inhibition
consequently leads to an increase of NDRG1 expression. We
supported this idea by demonstrating in Hep3B and U937 cells that
Hsp90 inhibitors lead to an increase of NDRG1, which is accompanied
by cell growth arrest, as measured by changes in cell cycle. The exact
mechanism of how cell growth arrest regulates NDRG1 needs further
examination. From our data, we can also speculate that HSP90 is
required for the maturation and/or stabilization of a negative regu-
lator, or transcriptional repressor of NDRG1. In the presence of GA or
17-DMAG, this “unidentiﬁed” HSP90-dependent protein is degraded,
therefore no longer active thus leading to an increase of NDRG1
transcriptional activity. In support of this theory, we demonstrated
that de novo protein synthesis is not necessary for the transcriptional
up-regulation of NDRG1 by GA (Fig. 3C). To date, only a few transcrip-
tional regulators of NDRG1 are known. Further studies that charac-
terize the NDRG1 promoter will help reveal the identity of negative
regulators of NDRG1 to help shed further light into the mechanism.
The HCC cell lines used in this study constitutively express both
phosphorylated and non-phosphorylated forms of NDRG1. In the
presence of GA or 17-DMAG, we observed a loss of the phosphory-
lated form of NDRG1. To explain this change, we focused on the
NDRG1 modifying kinases, SGK1 and GSK3β. Recently, Belova et al.
demonstrated that SGK1 forms a functional complex with Hsp90 that
is disrupted following treatment with GA [33]. Although total SGK1
protein is not degraded, there is a very rapid loss of SGK1 phos-
phorylation and subsequent inactivation by GA [33]. As previously
described, SGK1 initiates NDRG1 phosphorylation, by “priming” it for
further phosphorylation by GSK3β [7], therefore loss of SGK1 activity
by GA may alone be responsible for the loss of phosphorylated
NDRG1. Nonetheless, we investigated the effect of inhibiting Hsp90 on
the stability and activity of mature GSK3β as it has not yet been
identiﬁed as Hsp90 client protein. We demonstrated that Hsp90 and
GSK3β do interact, and that their interaction is impaired in the
presence of GA. Similar to other Hsp90 client proteins, total GSK3β
protein is decreased, along with the phosphorylation of the GSK3β
target β-catenin in the presence of GA. Inhibition of Hsp90 can also
affect upstream kinases that regulate GSK3β activity. However,
interfering with the activity of GSK3β regulating kinases, such as
Akt or PKA, would result in a block of GSK3β phosphorylation levels
and activity [42]. As shown in our study, GA-induced inhibition of
Hsp90 decreases total cellular levels of GSK3β, thus supporting the
idea that GSK3β is indeed a direct client protein of Hsp90.
In 2006, Lochhead et al. have shown that Hsp90 is necessary to
form a functional GSK3β transitional intermediate, whereby GA
inhibits GSK3β autophosphorylation, but it is not necessary for the
mature kinase [43]. In their rabbit reticulocyte lysate (RRL) system,
the level of mature GSK3 was not decreased in the presence of GA nor
was its ability to phosphorylate its serine/threonine substrate–muscle
glycogen synthase. Our data are not incompatible with the crucial role
of Hsp90 in its early stages of translation. However, if Hsp90were only
important during the protein folding stage of the GSK3β transitional
intermediate, wewould not expect to see a loss of total GSK3β protein
or loss of β-catenin phosphorylation. Although we agree that Hsp90 is
important for the maturation and autophosphorylation of GSK3β, we
propose that the mature protein and its serine/threonine activity are
also dependent on a functional Hsp90 protein. In fact, no loss of GSK3β
protein by GA was observed in experiments performed for 30min on
ice using RRLs [43], whereas we observed a loss of GSK3β in experi-
ments performed during a longer time period with endogenously
expressed mature protein (Fig. 7A–C).
Many protein substrates are functionally inhibited when phos-
phorylated by GSK3β and as a consequence, signals that suppress
GSK3β activity typically induce the function of GSK3β substrates. As
with other GSK3β targets that promote cancer development, it is
attractive to speculate that the unphosphorylated state of NDRG1 is
the active form, which maintains its anti-metastasis function,
1603V.M. Banz et al. / Biochimica et Biophysica Acta 1793 (2009) 1597–1603whereas the phosphorylated form represents the inactive state of the
protein, resulting in a loss of its function as a metastasis suppressor.
Supporting this theory, we observed the phosphorylated form of
NDRG1 in the HCC cell lines with uncontrolled cell growth (Fig. 2A
and B), whereas in primary hepatocyte cultures, no endogenous
expression of the phosphorylated protein is observed (Fig. 4A).
Others have demonstrated that NDRG1 is phosphorylated in primary
mouse tissue [7], however the phosporylation state as well as the
effect of phosphorylation on NDRG1 function within an organ could
be cell type speciﬁc. When the biological functions of NDRG1 are
ﬁnally revealed, the signiﬁcance of its phosphorylated state will
become more apparent.
In this paper we have provided new insights into the interaction of
Hsp90 with NDRG1. The stability of NDRG1 protein is not dependent
on the ATPase binding domain of Hsp90, however, inhibition of Hsp90
transcriptionally up-regulates total cellular levels and alters its post-
translational state by targeting the kinases responsible for its
phosphorylation. In addition we demonstrate for the ﬁrst time that
GSK3β requires Hsp90 for its stability and functional activity, thus
adding to the repertoire of cancer-related kinases affected by GA-
dependent targeting.
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